HIV-1针对整合酶抑制剂耐药研究进展

Progress on HIV drug resistance research against integrase inhibitors

在HIV抗病毒治疗过程中,耐药问题仍然是影响治疗效果的重要因素。整合酶抑制剂具有较高的遗传耐药屏障、较长半衰期,更加受到人们关注。但随着整合酶抑制剂的不断推广使用,各地也相继出现耐药报道。相关研究表明不同亚型毒株的耐药突变位点存在差异,这对整合酶抑制剂的治疗效果提出了挑战。因此整合酶抑制剂的耐药研究成了抗病毒治疗的一个不能回避的问题。本文将从整合酶抑制剂的种类及应用、国内外整合酶抑制剂的耐药流行情况、不同亚型的耐药突变位点差异所导致的药物敏感性差异及目前整合酶抑制剂面临的挑战及展望进行综述。

Drug resistance remains an important factor affecting the efficacy of HIV antiretroviral therapy.Integrase inhibitors have attracted more attention due to their higher genetic resistance barriers and longer half-lives.However,reports of drug resistance have emerged in various regions following the unremitting promotion and use of integrase inhibitors.Relevant research has shown that different strain subtypes have varying resistance mutation sites,which challenges the therapeutic efficacy of integrase inhibitors.Therefore,the study of integrase inhibitor resistance has become an unavoidable issue in antiviral therapy.This paper reviews the types and applications of integrase inhibitors,the prevalence of integrase inhibitor resistance both domestically and internationally,the differences in drug sensitivity caused by different subtypes of resistance mutation sites,and the challenges and prospects of integrase inhibitors currently.